# 胰腺癌临床试验报告

**生成日期**: 2025-06-07
**查询条件**: 胰腺癌相关的活跃临床试验
**查询范围**: 最近30天内新增或更新的试验
**试验总数**: 11
**智能翻译**: ✅ 已启用

> 📝 **说明**: 本报告提供中英文对照信息，关键医学术语保持原文以确保准确性。

## 试验列表

### 正在招募的试验

## 一项针对PARP1选择性抑制剂EIK1004（IMP1707）在晚期实体肿瘤患者中的研究。 (A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.)

**试验编号**: NCT06907043  
**正式标题**: 一项1/2期、开放标签、多中心、剂量递增及优化研究，旨在评估EIK1004（IMP1707）作为单药治疗在晚期实体瘤患者中的安全性、耐受性及活性。 (A Phase 1/2, Open-label, Multicenter, Dose-escalation, and Dose-Optimization Study to Evaluate the Safety, Tolerability, and Activity of EIK1004 (IMP1707) as Monotherapy in Participants With Advanced Solid Tumors)  
**疾病条件**: 晚期实体肿瘤 (Advanced Solid Tumors)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE1, PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: EIK1004-001（IMP1707-001） (EIK1004-001 (IMP1707-001))  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: Eikon Therapeutics  
**试验地点**: MD Anderson, Houston, United States; Fudan University Shanghai Cancer Center, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 130  

### 重要日期
**首次提交**: 2025-03-22  
**最后更新**: N/A  

### 联系信息
**联系人**: Sunny Chaudry, MS  
**电话**: 6319026200  
**邮箱**: chaudrys@eikontx.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06907043)

---

## 一项针对携带KRAS G12V突变晚期胰腺癌患者的IX001 TCR-T注射剂I期临床试验研究。 (A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation)

**试验编号**: NCT06898385  
**正式标题**: 一项针对携带KRAS G12V突变晚期胰腺癌患者的IX001 TCR-T注射剂I期临床试验研究。 (A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With KRAS G12V Mutation)  
**疾病条件**: 胰腺癌 (Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE1  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: IX001 T细胞受体-T细胞注射，氟达拉滨，环磷酰胺治疗。 (IX001 TCR-T injection, Fludarabine, Cyclophosphamide)  
**干预类型**: 生物制剂、药物、药物。 (BIOLOGICAL, DRUG, DRUG)  

### 试验信息
**主要发起方**: Sun Yat-sen University  
**试验地点**: Sun Yat-sen University Cancer Center, Guangzhou, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 9  

### 重要日期
**首次提交**: 2025-03-21  
**最后更新**: N/A  

### 联系信息
**联系人**: Yuhong Li  
**电话**: 87342487  
**邮箱**: liyh@sysucc.org.cn  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06898385)

---

## 一项研究，旨在了解BAY2927088片治疗在携带人类表皮生长因子受体2（HER2）突变的有实体肿瘤参与者中的疗效和安全性。 (A Study to Learn More About How Well Treatment With BAY2927088 Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2))

**试验编号**: NCT06760819  
**正式标题**: 一项开放式标签的二期篮式研究，旨在评估口服可逆性酪氨酸激酶抑制剂BAY 2927088在携带HER2激活突变的转移性或不可切除实体瘤患者中的疗效与安全性。 (A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations)  
**疾病条件**: 晚期实体肿瘤，HER2突变 (Advanced Solid Tumors, HER2 Mutation)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: BAY2927088  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: Bayer  
**试验地点**: University of Alabama at Birmingham, Birmingham, United States; City of Hope - Duarte Cancer Center, Duarte, United States; Florida Cancer Specialists & Research Institute - Fort Myers Cancer Center - Gladiolus, Fort Myers, United States  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 111  

### 重要日期
**首次提交**: 2024-12-18  
**最后更新**: N/A  

### 联系信息
**联系人**: Bayer Clinical Trials Contact  
**电话**: (+)1-888-84 22937  
**邮箱**: clinical-trials-contact@bayer.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06760819)

---

## 一项关于Ivonescimab联合化疗作为临界可切除胰腺癌新辅助治疗的研究。 (A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer)

**试验编号**: NCT06944106  
**正式标题**: 一项前瞻性、单臂、II期临床试验，评估Ivonescimab联合吉西他滨和阿比特龙（AG）方案作为临界可切除胰腺癌新辅助治疗的疗效和安全性。 (A Prospective, Single-arm, Phase II Clinical Study on the Efficacy and Safety of Ivonescimab Combined With Gemcitabine and Nab-paclitaxel (AG) Regimen as Neoadjuvant Treatment for Borderline Resectable Pancreatic Cancer)  
**疾病条件**: 胰腺癌 (Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: AK112  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: Tianjin Medical University Cancer Institute and Hospital  
**试验地点**: Tianjin Cancer Hospital Airport Hospital, Tianjin, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 30  

### 重要日期
**首次提交**: 2025-04-17  
**最后更新**: N/A  

### 联系信息
**联系人**: Li Huikai, MD  
**电话**: 18622228639  
**邮箱**: tjchlhk@126.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06944106)

---

## 适应性引导立体定向体部放疗联合化疗及新型药物Ivonescimab治疗胰腺癌（ASCEND）研究计划。 (Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND))

**试验编号**: NCT06844422  
**正式标题**: 适应性引导立体定向体部放疗联合化疗及新型药物Ivonescimab治疗胰腺癌（ASCEND）- 单臂 Ib/II期临床试验 (Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonescimab for Pancreatic Cancer (ASCEND) -A Single-Arm Phase Ib/II Trial)  
**疾病条件**: 胰腺癌 (Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE1, PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 伊沃尼单抗 (Ivonescimab)  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: Shandong Cancer Hospital and Institute  
**试验地点**: Shandong Cancer Hospital and Institute, Jinan, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 37  

### 重要日期
**首次提交**: 2025-02-19  
**最后更新**: N/A  

### 联系信息
**联系人**: Jinbo Yue, Doctor  
**电话**: 0531-67626442  
**邮箱**: jbyue@sdfmu.edu.cn  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06844422)

---

## CAR-NK细胞（CL-NK-001）在胰腺癌中的运用 (CAR-NK Cells (CL-NK-001) in Pancreatic Cancer)

**试验编号**: NCT06816823  
**正式标题**: 一项针对晚期胰腺癌患者使用CAR-NK细胞（CL-NK-001）的临床研究 (A Clinical Study of CAR-NK Cells (CL-NK-001) in Patients With Advanced Pancreatic Cancer)  
**疾病条件**: 胰腺癌 (Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE1  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: CL-NK-001是一种药物的代号。 (CL-NK-001)  
**干预类型**: 生物制品 (BIOLOGICAL)  

### 试验信息
**主要发起方**: Changhai Hospital  
**试验地点**: Changhai Hospital, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 30  

### 重要日期
**首次提交**: 2025-02-01  
**最后更新**: N/A  

### 联系信息
**联系人**: Yanfang Liu, MD PhD  
**电话**: +86-13124828854  
**邮箱**: liuyanfang00215@163.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06816823)

---

## 对晚期实体肿瘤患者进行的AZD4360研究。 (Study for AZD4360 in Participants With Advanced Solid Tumours)

**试验编号**: NCT06921928  
**正式标题**: 一项I/II期开放标签剂量递增和扩展研究，评估AZD4360在患有晚期实体瘤成人参与者中的安全性、药代动力学、药效学和疗效。 (A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD4360 in Adult Participants With Advanced Solid Tumours)  
**疾病条件**: 胃癌、胃食管交界癌、胆道癌、胰腺导管腺癌 (Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE1, PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: AZD4360  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: AstraZeneca  
**试验地点**: Research Site, Los Angeles, United States; Research Site, Providence, United States; Research Site, Houston, United States  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 117  

### 重要日期
**首次提交**: 2025-03-25  
**最后更新**: N/A  

### 联系信息
**联系人**: AstraZeneca Clinical Study Information Center  
**电话**: 1-877-240-9479  
**邮箱**: information.center@astrazeneca.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06921928)

---

## 他莫昔芬用于治疗胰腺实性假乳头状肿瘤晚期病例 (Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas)

**试验编号**: NCT06914674  
**正式标题**: 他莫昔芬用于治疗胰腺实性假乳头状肿瘤晚期病例 (Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas)  
**疾病条件**: 胰腺肿瘤 (Pancreatic Neoplasms)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 他莫昔芬 20 毫克 (Tamoxifen 20 mg)  
**干预类型**: DRUG  

### 试验信息
**主要发起方**: Fudan University  
**试验地点**: Shanghai Cancer Center, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 30  

### 重要日期
**首次提交**: 2025-03-31  
**最后更新**: N/A  

### 联系信息
**联系人**: Huanyu Xia MD  
**电话**: 86 21 64031446  
**邮箱**: xiahuanyu@fudanpci.org  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06914674)

---

## 腹膜转移性胰腺癌患者腹腔热灌注化疗联合静脉化疗的安全性及有效性：II期临床试验 (The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial)

**试验编号**: NCT06946901  
**正式标题**: 腹膜转移性胰腺癌患者腹腔热灌注化疗联合静脉化疗的安全性及有效性：II期临床试验 (The Safety and Effectiveness of Hyperthermic Intraperitoneal Chemotherapy Combined With Intravenous Chemotherapy for Peritoneal Metastatic Pancreatic Cancer, a Phase II Clinical Trial)  
**疾病条件**: 腹腔热灌注化疗，腹膜转移性胰腺癌治疗。 (Hyperthermic Intraperitoneal Chemotherapy, Peritoneal Metastatic Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 腹腔高温化疗（HIPEC）联合顺铂 + 全身AG化疗方案。 (Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Cisplatin + Systemic AG Chemotherapy)  
**干预类型**: COMBINATION_PRODUCT  

### 试验信息
**主要发起方**: Shanghai Zhongshan Hospital  
**试验地点**: The Second Xiangya Hospital of Central South University, Changsha, China; Zhongshan Hospital, Fudan University, Shanghai, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 90  

### 重要日期
**首次提交**: 2025-04-19  
**最后更新**: N/A  

### 联系信息
**联系人**: Wenquan Wang, Dr  
**电话**: 86 13701874954  
**邮箱**: wang.wenquan@zs-hospital.sh.cn  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06946901)

---

## 白蛋白结合型紫杉醇与吉西他滨联合或不联合S-1作为晚期胰腺癌的一线治疗。 (Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer)

**试验编号**: NCT06789679  
**正式标题**: 随机二期临床研究：以白蛋白结合型紫杉醇和吉西他滨，联合或不联合S-1作为局部晚期或转移性胰腺癌一线治疗的比较研究。 (Randomized Phase II Clinical Study of Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Cancer)  
**疾病条件**: 胰腺腺癌 (Pancreatic Adenocarcinoma)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 吉西他滨、白蛋白结合型紫杉醇、S-1、吉西他滨、白蛋白结合型紫杉醇。 (Gemcitabine, albumin-bound paclitaxel, S-1, Gemcitabine, albumin-bound paclitaxel)  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: Cancer Institute and Hospital, Chinese Academy of Medical Sciences  
**试验地点**: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 128  

### 重要日期
**首次提交**: 2025-01-17  
**最后更新**: N/A  

### 联系信息
**联系人**: Lin Yang, Doctor  
**电话**: 13681015148  
**邮箱**: linyangcicams@126.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06789679)

---

## 一项关于TQB2916注射剂联合盐酸吉西他滨注射剂和白蛋白结合型注射用紫杉醇一线治疗转移性胰腺癌的临床研究 (A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochloride for Injection and Paclitaxel for Injection (Albumin-bound Type))

**试验编号**: NCT06962267  
**正式标题**: 一项II期临床试验，评估TQB2916注射剂联合吉西他滨和白蛋白紫杉醇作为转移性胰腺癌一线治疗的疗效与安全性。 (A Phase II Clinical Study to Evaluate the Efficacy and Safety of TQB2916 Injection Combined With Gemcitabine and Albumin-paclitaxel as First-line Treatment for Metastatic Pancreatic Cance)  
**疾病条件**: 胰腺癌 (Pancreatic Cancer)  
**试验状态**: RECRUITING  
**试验阶段**: PHASE2  
**研究类型**: INTERVENTIONAL  

### 干预措施
**干预名称**: 注射用TQB2916，化疗 (TQB2916 Injection, Chemotherapy)  
**干预类型**: DRUG, DRUG  

### 试验信息
**主要发起方**: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.  
**试验地点**: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China  
**开始日期**: N/A  
**预计完成日期**: N/A  
**招募人数**: 50  

### 重要日期
**首次提交**: 2025-04-30  
**最后更新**: N/A  

### 联系信息
**联系人**: Yi Ba, Doctor  
**电话**: 13752157916  
**邮箱**: Bayi@tjmuch.com  

**试验链接**: [ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06962267)

---

